The phase II trial expands on the positive results from the phase I portion by including older adults aged 60-84 years of age as approximately 50% of the trial's population. NVX-CoV2373 is a stable, prefusion protein made using Novavax's nanoparticle technology and proprietary Matrix-M adjuvant.

The study is a randomized, placebo-controlled, blinded study that will assess the drug at two doses (5 and 25 µg) each with 50 µg of adjuvant. Approximately 1,500 healthy participants are expected to enroll in the trial at 40 sites in the U.S. and Australia.

Funding for the trial is provided by the Coalition of Epidemic Preparedness Innovations.

AGC expands partnership with Novavax in U.S.
AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate...

Novavax licenses COVID-19 vaccine to Takeda in Japan
Novavax and Takeda Pharmaceutical have formed a partnership for the development, manufacturing, and commercialization in Japan of NVX-CoV2373, Novavax's...

Novavax, Fujifilm begin large-scale manufacturing of COVID-19 vaccine
Novavax and Fujifilm Diosynth have signed an agreement covering the bulk manufacture of Novavax's COVID-19 vaccine candidate, NVX-CoV2373, at Fujifilm's...

$1.6B awarded to Novavax for COVID-19 vaccine
Novavax was awarded $1.6 billion by the U.S. government through Operation Warp Speed to deliver 100 million doses of a COVID-19 vaccine as early...

AGC to manufacture adjuvant for Novavax COVID-19 vaccine
AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus...